A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors
第一作者单位：[1]Capital Med Univ, Beijing Tiantan Hosp, Neuro Oncol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Li W.,Kang Z.,Li S.,et al.A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors[J].ANNALS OF ONCOLOGY.2022,33(7):S675-S676.doi:10.1016/j.annonc.2022.07.436.
APA：
Li, W.,Kang, Z.,Li, S.,Lin, Y.,Li, Y....&Qiu, J..(2022).A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors.ANNALS OF ONCOLOGY,33,(7)
MLA：
Li, W.,et al."A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors".ANNALS OF ONCOLOGY 33..7(2022):S675-S676
医学